Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
351. |
ECCT/21/10/02 | RESOLVE A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Janet Oyieko Site(s) in Kenya 1. KEMRI CCR- Butere County Hospital (Kisumu county) 2. Strathmore University (Nairobi City county) 3. KEMRI Kondele Children’s Hospital (Kisumu county) 4. KEMRI/CRDR Siaya Clinical Research Annex (Siaya county) 5. KEMRI CRDR Clinical Research Clinic Nairobi (Nairobi City county) 6. Gertrude’s Children’s Hospital (Nairobi City county) |
14-07-2022 |
View |
352. |
ECCT/21/07/01 | RESOLVE A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell DiseaseA Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Jessie Nyokabi Githanga Site(s) in Kenya 1. Strathmore University Medical Center (Nairobi City county) 2. KEMRI Kondele children\'S Hospital (Kisumu county) 3. Gertrude\'s Children\'s Hospital (Nairobi City county) |
10-11-2021 |
View |
353. |
ECCT/24/10/05 | Cabotegravir + Rilpivirine Inj A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Aga Khan University Hospital Nairobi (Nairobi City county) 2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county) 3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho (Kericho county) 4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county) 5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
29-04-2025 |
View |
354. |
ECCT/24/10/04 | Cabotegravir + Rilpivirine Inj A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project Clinical Research Centre (Kericho county) 2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county) 3. Aga Khan University Hospital Nairobi (Nairobi City county) 4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county) 5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
30-04-2025 |
View |
355. |
ECCT/25/07/05 | Cabotegravir + Rilpivirine Lon A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studie |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Aga Khan University Hospital (Nairobi City county) 2. Moi University Clinical Research Centre (Elgeyo/Marakwet county) 3. KEMRI-WRP (Kericho county) 4. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
31-10-2025 |
View |
356. |
ECCT/24/07/02 | TMC278LAHTX4002 A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studies |
Principal Investigator(s) 1. Reena Shah Site(s) in Kenya 1. Aga Khan University Hospital Nairobi (Nairobi City county) 2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county) 3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho, Kenya (Kericho county) 4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county) 5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Nairobi City county) |
16-04-2025 |
View |
357. |
ECCT/23/10/02 | MATRIX-001 protocol A Phase I Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Pharmacokinetics, and Modeled Pharmacodynamics of a Vaginal Insert Containing Tenofovir Alafenamide and Elvitegravir |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD Thika |
11-01-2024 |
View |
358. |
ECCT/25/12/03 | ITU512 Study - Site 6002 A Phase I/II clinical study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ITU512 in healthy participants and patients with sickle cell disease |
Principal Investigator(s) 1. Doreen Terry Karimi Mutua Site(s) in Kenya 1. Site 6001: International Cancer Institute (Uasin Gishu county) 2. Site 6002: Gertrude’s Children’s Hospital (Nairobi City county) 3. Site 6003: KEMRI Kondele Children’s Hospital (Kisumu county) |
23-10-2026 |
View |
359. |
ECCT/25/12/02 | ITU512 Study - Site 6003 A Phase I/II clinical study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ITU512 in healthy participants and patients with sickle cell disease |
Principal Investigator(s) 1. Godfrey Allan Otieno Site(s) in Kenya 1. Site 6001: International Cancer Institute (Uasin Gishu county) 2. Site 6002: Gertrude’s Children’s Hospital (Nairobi City county) 3. Site 6003: KEMRI Kondele Children’s Hospital (Kisumu county) |
23-10-2026 |
View |
360. |
ECCT/13/07/01 | HIVCORE004/N004 A phase I/IIa clinical trial of universal HIV-1 vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and ChAdV63.HIVconsv in combined regimens in healthy HIV-1/2-negative adults in Nairobi. |
Principal Investigator(s) 1. Prof. Walter Godfrey Jaoko Site(s) in Kenya KAVI-KANGEMI RESEARCH SITE |
19-06-2013 |
View |